And that's a wrap for #DAVAWhistlerHeme 2024!

Thank you again to all of our faculty and industry partners who made the trip to participate in this conference. It was truly an enriching and educational experience for everyone!

Wrapping up #DAVAWhistlerHeme with teaser from Dr. Paolo Strati MD Anderson Cancer Center, phase 1 trial of evorpacept and R2 for treatment of pts with r/r B-NHL

Evorpacept increases antibody-dependent phagocytosis in macrophages

Tune in to AACR on April 9th to see the results!

Will novel agents in CLL decrease risk of RT? Dr. Jean-Nicolas Champagne shares data from 219 RT patients, 144 pre- and 75 post-2016.

Post 2016:
⬆️Time from txt to RT
⬇️PS at time of RT
⬇️OS after RT

RT remains challenging. More tolerable therapies are needed in the modern era.

Starting Now: Approaches to Richter's and Enhancing Macrophage Function
Moderated by Dr. Alessandra Ferrajoli

Dr. John Baird returns to the stage to discuss BAFF-R as a target to overcome antigen escape mechanisms of resistance

DL2 currently enrolling in MCL, LBCL, FL, MZL: classic.clinicaltrials.gov/ct2/show/NCT05…
Ph 1 for B-ALL also enrolling: clinicaltrials.gov/study/NCT04690…

L. Elizabeth Budde, M.D., Ph.D.
City of Hope

CD30 CAR-T has been disappointing in HL.

Dr. Jakub Svoboda shares 'engine fine tuning' w/ CRISPR knock out BTLA-HVEM, a CPI that is enriched in HL and suppresses immune activation

Murine models show enhanced CD30 CAR-T function with BTLA KO, clinical trials in planning stage

Dr. Jakub Svoboda Penn Medicine discusses armored huCART19-IL18 with encouraging early results in CD19+ lymphoma

No new safety signals w/ IL-18
CRS/ICANS rates comparable, reversible
82% ORR at 3 mo

Enrollment completed for NHL and continues for CLL, ALL
clinicaltrials.gov/study/NCT04684…

Krish Patel reviews rationale for dual targeting CD19/CD20. CD20 is expressed independent of CD19, targeting both may improve durability of response by limiting antigen escape.

C-CAR039 demonstrated deep and durable response as well as improved safety

cancer.gov/research/parti…

L. Elizabeth Budde, M.D., Ph.D. shares preclinical data for CD79b-targeting CAR-T products

CD79b is a B-cell lineage marker expressed across most B-cell NHL, independent of CD19 expression

Two phase 1 trials are actively recruiting:
clinicaltrials.gov/study/NCT05773…
classic.clinicaltrials.gov/ct2/show/NCT06…

Dr. John Baird City of Hope shares promising phase 1 experience of CRG-022 in LBCL after prior autologous CAR-T

Pivotal phase 2 trial now enrolling: classic.clinicaltrials.gov/ct2/show/NCT05…

Krish Patel kicks off our final CAR-T panel by walking through the approach to sequencing CAR-T therapies

When choosing a 2nd CAR-T, you must consider
➖Antigen loss (different antigen❓)
➖T-cell fitness (different effector cell❓)
➖Immunologic resistance (armored CAR-T❓)

Starting Now: Novel CAR-Ts for B-cell Malignancies
Moderated by Dr. Krish Patel Krish Patel

A fantastic final MM lecture of #DAVAWhistlerHeme !

Scott Goldsmith shares preclinical efficacy of Actinium-225-DOTA daratumumab radioimmunotherapy and ongoing clinical trial for triple-class refractory MM

clinicaltrials.gov/study/NCT05363…

Which is your favorite candidate name? 😅

Sagar Lonial MD predicts P300 will be the next 'it' molecule in MM

P300 co-activates important mediators of resistance to IMiDs, which allows for synergistic activity between IMiDs and P300 inhibitors

Scott Goldsmith reviews the difference between IMiDs and CELMoD mezigdomide

Mezigdomide 'plays well in the sandbox, showing promising safety/efficacy in combination w/ existing MM therapies

SUCCESSOR-1: Mezi + Vd classic.clinicaltrials.gov/ct2/show/NCT05…
SUCCESSOR-2: Mezi + Kd classic.clinicaltrials.gov/ct2/show/NCT05…

Dr. Jeffrey Zonder shares promising data for iberdomide as post-ASCT maintenance in MM.

Notably, ~50% of patients saw responses improve over the first year of IBER maintenance, and 1yr PFS was 90%

EXCALIBER trial will compare IBER vs LEN maintenance
classic.clinicaltrials.gov/ct2/show/NCT05…

Starting Now: Multiple Myeloma, Targeting the Cereblon and Ikaros Pathway
Moderated by Dr. Adam Cohen

Dr. Craig Portell UVA discusses the biology of CDK9 in CLL and rationale for targeting this protein

CDK9 affects MCL-1 which is overexpressed in some CLL patients with acquired venetoclax resistance

Unlikely to be used as monotherapy, but phase 1 combination trials are ongoing

Dr. Stephen Spurgeon provides 14-mo update to waveLINE-001 trial. Notably, there is a signal in MCL, with 100% of MCL patients BTKi-exposed and 82% with PD on BTKi.

ZV could be a potential salvage therapy for these MCL patients

ROR-1 is an appealing target for CAR, BsAbs, etc

Starting Now: New Drugs in Lymphoid Malignancies
Moderated by Dr. Craig Portell at UVA